Lexicon re structures
After a years-long uphill battle for Lexicon Pharmaceuticals and its insulin adjunct prospect Zynquista (sotagliflozin), the company will move forward with no commercial sales team and no further promotional efforts for its Inpefa, a heart failure version of sotagliflozin approved by the FDA in 2023.
The company will still manufacture the drug and provide it to patients and existing prescribers. The change will prompt a 60% reduction of the company's workforce, effective December 31st. Lexicon expects to cut full-year operating costs by $100 million with the plan.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins